Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, International Study Comparing the Efficacy and Safety of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer

NCT02929576 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02929576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02929576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, International Study Comparing the Efficacy and Safety of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Withdrawn
Start date
September 30, 2016
Completion date
Not reported
Enrollment
0 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer